Literature DB >> 2076390

Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension.

J Sasaki1, K Arakawa.   

Abstract

The effects of short- and long-term administration of nifedipine on serum lipids, lipoproteins, and apolipoproteins (apo) were studied. Administration of nifedipine capsule for 4 months significantly decreased triglycerides and increased the HDL2 cholesterol and the HDL2/HDL3 cholesterol ratio. No significant changes in serum lipids and lipoproteins were observed during short-term therapy with slow-release nifedipine tablets. Following administration of tablets for 24 months, the LDL/HDL cholesterol ratio, apo B, and apo B/apo A-I ratio increased at 12 months, but reverted to baseline values at 24 months. Apo E levels were decreased significantly at 24 months. No significant changes were noted in total cholesterol, triglyceride, HDL cholesterol, HDL2,3 cholesterol, apo A-I, apo A-II, apo C-II, or apo C-III levels during long-term therapy with slow-release nifedipine tablets. These results indicate that nifedipine has a neutral or even favorable effect on lipoprotein metabolism. However, a prospective well-controlled study would be required to finally establish this effect. This finding strengthens the indications for using nifedipine as a first-line drug in the long-term treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076390     DOI: 10.1007/BF02018313

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  10 in total

1.  Enzymatic determination of total serum cholesterol.

Authors:  C C Allain; L S Poon; C S Chan; W Richmond; P C Fu
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

Review 2.  Antihypertensive treatment and serum lipoproteins.

Authors:  P Weidmann; D E Uehlinger; A Gerber
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

3.  [A new determination of the neutral fats in blood serum and tissue. I. Principles, procedure, and discussion of the method].

Authors:  M Eggstein; F H Kreutz
Journal:  Klin Wochenschr       Date:  1966-03-01

Review 4.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

5.  Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension.

Authors:  P E Pool; S C Seagren; A F Salel
Journal:  Am J Cardiol       Date:  1985-12-06       Impact factor: 2.778

6.  Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.

Authors:  K P Ohman; L Weiner; H von Schenck; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Long-term results with verapamil in essential hypertension and its influence on serum lipids.

Authors:  G R Lewis
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

8.  Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia.

Authors:  P G Hugenholtz; H R Michels; P W Serruys; R W Brower
Journal:  Am J Cardiol       Date:  1981-01       Impact factor: 2.778

9.  The effect of nifedipine on plasma lipids in patients with essential hypertension.

Authors:  A Lehtonen; A Tanskanen; H Lehto; P Jarvensiven
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-07

10.  Antihypertensive and metabolic effects of diltiazem and nifedipine.

Authors:  K L Schulte; W A Meyer-Sabellek; A Haertenberger; H M Thiede; L Roecker; A Distler; R Gotzen
Journal:  Hypertension       Date:  1986-10       Impact factor: 10.190

  10 in total
  1 in total

1.  Controversial Role of Lecithin:Cholesterol Acyltransferase in the Development of Atherosclerosis: New Insights From an LCAT Activator.

Authors:  Cecilia Vitali; Marina Cuchel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-23       Impact factor: 8.311

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.